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INTRODUCTION 
 
Yellow oleander poisoning is the most common plant poisoning 
in South India. It being a cardiac glycoside has significant cardiac 
toxicity and a mortality rate of about 10%1. In Madras Medical 
College, Chennai, Poison Centre alone, there were 210 persons 
admitted with oleander poisoning during the period September 1, 2001 
to May 31, 2004 with a mortality rate of 11.43%2.   
 
Specialized treatment with antidigoxin fab fragments and 
cardiac pacing is expensive and not widely available.  Multiple dose 
activated charcoal binds cardiac glycosides in the gut lumen and 
promotes their elimination.  Aim of the study was to assess the 
efficacy of multiple dose activated charcoal in the treatment of 
patients with yellow oleander poisoning.   
 
During the period June 1, 2004 to May 31, 2005 there were 63 
cases of yellow oleander poisoning at the IMCU / Poison Centre of 
Madras Medical College, Chennai and the study included 47 patients 
who met the inclusion criteria. 
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OBJECTIVES OF THE STUDY 
 
 
 Aim of the study was to assess between the two arms of the trial 
whether: 
 
a)  Any significant reduction in mortality. 
 
b)  Any reduction in occurrence of major or life threatening cardiac 
arrhythmias. 
 
c)  Any reduction in the doses of other drugs-atropine- needed. 
 
d)  Any significant reduction in the number of days of stay in the 
hospital. 
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REVIEW OF LITERATURE 
 
 In nature a wide variety of cardiotonic steroids is found in 
plants, the insects that feed on them and in the parotid glands and skin 
of some toads. All these natural drugs contain a steroid nucleus with a 
lactone ring, five membered in the case of cardenolides, and six 
membered in bufadienolides. 
 
 The cardiac glycosides have a carbohydrate or sugar moiety 
attached through an oxygen bridge to carbon 3 of the ‘A’ ring of the 
steroid.   
 
Mechanism of action of cardiac glycosides  
 
 The myocardial effects of these compounds are attributable to 
inhibition of transmembrane Na+ / K+ ATPase pump3. 
 
 Cardiac glycosides bind selectively to extra cellular face of the 
membrane associated Na+ K+ ATPase of myocardial fibres and inhibits  
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this enzyme.  This indirectly results in intracellular Ca2+ 
accumulation.   
 
During depolarization Ca2+ ions enter the cell driven by the 
steep Ca2+ gradient through voltage sensitive Ca2+ channels.  This 
triggers release of Ca2+ stored in sarcoplasmic reticulum and a fraction 
is extruded by 3 Na+ / 1 Ca2+ exchange.  During the phase 3 of action 
potential membrane Na+ / K+ ATPase move 3 intracellular Na+ ions 
for 2 extracellular K+ ions.   
 
 The increase in cytostolic Na+ over normal due to inhibition of 
Na+ K+ ATPase by cardiac glycosides reduces transmembrane gradient 
of Na+, which drives extrusion of Ca2+.  The excess Ca2+ remaining in 
cytosol are taken up by sarcoplasmic reticulum which progressively 
get loaded with more and more Ca2+ resulting in increase force of 
contraction of heart and conduction abnormalities.  In addition, 
depletion of intracellular K+ aggravates the conduction disturbances. 
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Oleander plant & poisoning 
 
 The ‘Apocyanaceae’ are sources of African arrow poisons and 
also contain many of the most beautiful but deadly tropical flowering 
shrubs such as ‘Nerium Oleander’, pink or white oleander and 
‘Thevetia peruviana’, yellow oleander4. 
 
 Ingestion of oleander seeds or leaves is a common cause of 
accidental poisoning worldwide, particularly among children5.  The 
oleander seeds have been used for suicide, homicide, abortion and as 
herbal remedies in India, Thailand, Brazil and elsewhere6. Cases of 
oleander poisoning have been reported from places as diverse as 
Hawaii, Southern Africa, Australia, Europe the Far East and the 
United States.   
 
 Deliberate self poisoning with seeds of yellow oleander is 
extremely common in South India and Sri Lanka.  Yellow oleander 
glycosides proved effective in patients with heart failure and atrial 
fibrillation in studies carried out in the 1930s7 and more recently in 
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India.  However, digitoxin or oubain have been preferred 
because of less frequent gastrointestinal side effects. 
 
White or sweet scented oleander 
 
 Nerium Odorum or sweet-scented oleander belongs to 
Apocyanaceae, and is grown in India for its beautiful white or pink 
flowers’ which are given as offerings in temples. It has lanceolate 
leaves and has a two follicled fruit which contains numerous seeds.  
 
 All plants of the plant are poisonous. S R Naidu and his co-
workers have isolated from the plant an active principle, nerin 
(C35H50O10), which is a pure, white, crystalline glycoside with 
digitalis like action. It is sparingly soluble in water, ether, petroleum 
ether and benzene, but dissolves readily in alcohol, acetone and 
chloroform, and melts at 123 degree Celsius. 
 
The plant, especially the leaf, bark and flowers are used to treat 
several diseases like skin diseases, infected wounds, snake bite, 
dysmenorrhoea, epilepsy etc. 
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Symptoms 
  
Symptoms of oleander poisoning include gastrointestinal 
irritation and digitalis like action on the heart. There is also difficulty 
in swallowing and articulation, abdominal pain, vomiting, profuse 
frothy salivation and diarrhoea. 
  
The pulse is slow and later becomes rapid and weak. Cardiac 
arrhythmias may develop. Respiration is quick, followed by dilated 
pupils, muscular twitchings, tetanic spasms, drowsiness, 
unconsciousness, coma and death. Lockjaw frequently occurs. 
 
 
Fatal dose 
 
 It is not certain what quantity of white oleander will prove fatal. 
About 16.6 gram of the root may be considered an average fatal dose 
for an adult, though there have been instances where a little more than 
4 gram of the bark have produced lethal poisonous symptoms. 
  
 8
 Yellow Oleander 
 
‘Thevetia Peruviana” or yellow oleander is a plant belonging to 
Apocyanaceae, and is widely cultivated as an ornamental shrub in 
gardens in the plains in India. It has linear lanceolate leaves8,9, large, 
yellow bell-shaped flowers and a green globular fruit containing a 
single nut, light brown in colour and triangular in shape with two 
cells, each enclosing a pale yellow seed.   
 
 
The toxins   
 
The yellow oleander contains atleast eight different cardiac 
glycosides, including thevetin-A, thevetin-B (cerberoside), thevetoxin, 
nerifolin, peruvoside and ruvoside.6,9 All parts of the plant are 
dangerous, especially the seeds.   
  
Thevetin C27H84O12 is sparingly soluble in water, but dissolves 
readily in ether and chloroform, and melts at 178°C.10   
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Its paralytic action is not so well marked as that of 
‘nerin’, the active principle of Nerium Odorum, the white oleander.   
 
Ghatak11 isolated from the kernels of the seeds of yellow 
oleander, thevetin and thevetoxin. The first glycoside, thevetin was 
obtained in the form of snow white, slender needles melting at 192°C 
by recrystalization from dilute alcohol.   
 
The second glycoside, thevetoxin; when recrystallised twice 
from hot water was obtained in slender, shining, silky needles melting 
at 178°C.  Both the glycosides were thought to be highly poisonous, 
but Bhatia and Lall12 have demonstrated from experiments that 
thevetoxin is less toxic than thevetin. Prof. S. Rangaswami has 
isolated peruvoside, said to be one of the world’s best cardiac drug 
from yellow oleander. 
 
Fatal dose 
 It is not certain what constitutes a fatal dose of yellow oleander.  
One to two seeds may be fatal to a child where as eight to ten seeds 
are considered to be fatal in an adult10,13. 
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Clinical features 
 
 Symptoms of poisoning include a burning pain in the mouth and 
dryness of the throat, tingling and numbness of the tongue, vomiting 
and often diarrhoea, headache, dizziness, dilated pupils and fainting.  
Ataxia, seizures and hypotension may also occur.  Varying degrees of 
heart block and collapse sets in and death can occur.  
 
Cardiac arrhythmias in oleander poisoning 
 
 Most cases of cardiac glycoside poisoning reported in the 
literature have been in patients overdosed during digitalis therapy for 
cardiovascular disease14.  Eddleston et al15 reported that they found 
clear differences in the incidence of particular arrhythmias between 
oleander and digitalis poisoning.  
 
 Ventricular ectopics and tachycardias are common in digoxin 
poisoned patients, but are rare in oleander poisoned patients, who are 
normally young and previously healthy.  Among 89 seriously ill 
patients 53% had AV node conduction block, white 62% had sinus 
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node block; 30% had conduction block affecting both nodes. 
Only 1% had ventricular tachycardias and 8% had ventricular 
ectopics. These differences may be explained in part by the Serum K+ 
levels before glycoside ingestion.   
 
 Most patients with severe digitalis poisoning have pre-existing 
hypokalemia attributable to the many other drugs that they are taking.  
Few of the patients who ingested yellow oleander were on any 
medication, and would have been normokalemic before the poisoning.  
  
 Severe oleander poisoning was associated with elevated serum 
potassium levels16.  A similar relationship has been found in patients 
taking large suicidal overdoses of digoxin17,18, and those ingesting 
toad skin poisons19.  This is explained by inhibition of the Na+ / K+ 
ATPase pump by the cardiotoxic steroids. 
 
Treatment of oleander poisoning 
 
 Routine treatment in our hospitals is gastric lavage and one oral 
dose of activated charcoal on admission, followed by intravenous 
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atropine, isoprenaline or both for bradyarrhythmias.  Patients 
who do not respond to this treatment are given temporary cardiac 
pacing, often in a special unit, to which they must be transferred.   
 
 Eddleston and colleagues20 have shown that antidigoxin 
antibody fab fragments can reduce life threatening cardiac arrhythmias 
and the need for cardiac pacing in oleander poisoning. However, their 
study was too small to determine whether treatment with the antibody 
had an effect on death rates.  Furthermore, the use of the antibody is 
limited by its high cost and because it is rarely available in the rural 
and secondary care hospitals in which the patients with yellow 
oleander poisoning seek treatment. 
 
 At present patients with oleander poisoning who come to rural 
health centres are transferred to nearest secondary hospital for routine 
treatment and cardiac monitoring.  Those showing evidence of cardiac 
conduction block are then transferred as quickly as possible to CCU 
for temporary cardiac pacing.   
 
 13 
 The cost of transfers together with temporary 
pacemakers and CCU beds is very high.  Moreover a significant 
number of patients die before they reach CCU. 
 
 This indicates that a form of treatment appropriate for rural 
hospitals is urgently required.  H.A. de Silva and colleagues21 had 
shown that multiple dose activated charcoal is effective in reducing 
deaths and life threatening cardiac arrhythmias after yellow oleander 
poisoning.  It could also reduce the cost of treatment. 
 
Multiple dose activated charcoal  
 
 Activated charcoal is inexpensive and widely available.  
Charcoal adsorbs ingested poison within the gut lumen, allowing the 
charcoal-toxin complex to be evacuated with stool. The complex can 
also be removed from the stomach by induced emesis or lavage.  
 
 In vitro, charcoal adsorbs ≥ 90% of most substances when given 
in an amount equal to 10 times the weight of the substance22.  
Repetitive oral dosing with charcoal can enhance the elimination of 
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previously absorbed substances by binding them within the 
gut as they are excreted in the bile, secreted by gastrointestinal cells 
or passively diffuse in to the gut lumen (reverse absorption or 
enterocapillary exsorption). 
 
 After absorption into the systemic circulation, cardiac 
glycosides such as digoxin are secreted into the gut lumen by the 
action of P-Glycoprotein.  In the gut, activated charcoal binds the 
secreted glycoside and encourages further secretion, there by causing 
a rise in glycoside excretion.  
 
 In pigs, repeated doses of activated charcoal reduced the half 
life of digoxin given intravenously from 65 hours to 17 hours and 
increased clearance from 2.3 ml/minute/kg to 7.1 ml/minute/kg23.  
 
In ten healthy volunteers who received intravenous digoxin, 
repeated doses of activated charcoal increased total body clearance 
from 12 L/hour to 18 L/hour and reduced the half life from 37 hours to 
22 hours24.  In addition Dasgupta et al demonstrated the efficacy of 
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activated charcoal in removing oleander leaf extract and 
oldeandrin from human serum by measuring apparent digoxin 
concentration.25 
 
 Side effects of activated charcoal, though not frequent, include 
mechanical obstruction of the airway, aspiration, vomiting and bowel 
obstruction and infarction caused by inspissated charcoal. 
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MATERIALS AND METHODS 
 
Patients 
 
 Patients admitted during the period, June 1, 2004 to May 31, 
2005 to the poison centre of Madras Medical College, Chennai, were 
included for the trial.  Patients aged 12 – 70 years who were admitted 
within 24 hours of ingestion of yellow oleander seeds were eligible for 
inclusion. 
 
 Patients who had taken another drug such as alcohol, 
organophosphates, paracetamol or sedatives, had other debilitating 
diseases like diabetes mellitus, hepatic or renal disease, heart failure 
or malignant disease, had abdominal surgery within the past 1 year 
were excluded from the trial.  
 
  Patients with known hypersensitivity to activated charcoal, 
those with severe infections and pregnant and lactating women also 
excluded. Patients who received corticosteroids as part of treatment, 
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as suggested by cardiologist, were also excluded from the 
study, to avoid confounding. 
 
 Patients were informed about the nature, objectives, importance, 
expected benefits and possible adverse effects of the treatment.  If the 
patient did not give the consent, permission from a parent, spouse or 
guardian was sought.  Patients were told they were free to withdraw 
from the trial at any time if they wished to do so, without any 
prejudice to subsequent management. 
 
Procedures 
 
 On admission, all patients were assessed and received standard 
treatment of yellow oleander poisoning i.e., gastric lavage, one 50g 
dose of activated charcoal, and atropine as needed.  Cardiopulmonary 
resuscitation was given when required.  Concentrations of serum 
potassium, sodium, and creatinine and blood urea were measured at 
base line, did electrocardiographs serially and monitored the cardiac 
rhythm. Patients were assessed and treated throughout the trial in 
accordance with a standardised management protocol (given separate). 
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 6 hours after admission patients were randomly 
allocated either multiple doses of activated charcoal (50g) or placebo 
(sterile water) every 6 hours.  The investigator was not involved in the 
patient allocation into the two arms.  Also he was unaware of the 
patient’s treatment allocation during the trial. 
 
 Patients were asked to drink the activated charcoal or sterile 
water and used a nasogastric tube for those who were unable to do so.  
The poison centre staffs, who supervised administration of activated 
charcoal or sterile water, did not participate in clinical assessment or 
management of patients. 
 
 Activated charcoal was given in a dose of 50g dissolved in water 
to 400ml every 6 hours for 3 days.  An equivalent amount of sterile 
water was given to those on placebo.  Patients who had nausea or 
vomiting after the trial began were given 10mg of intravenous 
metoclopramide as required.  Patients were monitored for 
abnormalities in cardiac rhythms and electrocardiograms were done if 
arrhythmias were detected. Patients were monitored until discharge 
from hospital or death. 
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 Death was used as primary end point.  Patients were assessed for 
the frequency of life threatening cardiac arrhythmias (defined in this 
trial as second degree AV block type II, 2:1 second degree AV block, 
complete heart block, ventricular tachycardia, or any arrhythmia with 
hemodynamic compromise) or major cardiac arrhythmias (defined in 
this trial as life threatening arrhythmias as above plus any conduction 
disturbances of SA node or AV node or conducting system other than 
non-specific ST-T changes).  The cardiac arrhythmias were assessed at 
presentation and monitored with serial ECGs. 
 
 Those with major or life threatening arrhythmias were treated 
with antiarrhythmic drugs including isoprenaline, lignocaine and 
amiodarone.  None of the patients were treated with antidigoxin 
antibody fab fragments.  Two patients received temporary pacing but 
both patients expired, one in the study group and one in the excluded 
group.  No other patients in the study group received temporary 
pacing. 
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 Doses of atropine used were calculated as well as the 
duration of hospital stay.  Discharge criterion was sinus rhythm with 
rate greater than 60 per minute for 24 hours. 
 
 Patient’s tolerance of charcoal by recording response to 
treatment was assessed.  Bowel sounds were monitored regularly, and 
precautions were taken to help patients to avoid aspiration of activated 
charcoal, especially in those who received treatment via a nasogastric 
tube. 
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TRIAL PROFILE 
 
 
 
 
 
63 patients admitted for 
oleander poisoning 
23 completed trial 
24 Activated charcoal 23 Placebo 
O death 2 deaths 
47 randomised 
16 excluded 
     2 died before randomisation 
     2 were known hypertensives 
     2 took alcohol along with oleander 
     10 received corticosteroids 
 
24 completed trial 
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TREATMENT PROTOCOL 
 
1. Routine treatment after poisoning for ALL patients - 
gastric lavage, one dose of activated charcoal, IV access, 
cardiopulmonary resuscitation. 
 
2. Randomly allocate patients into two sets who meet 
inclusion criteria. 
 
Exclusion Criteria  
 
• Who had taken another drug (alcohol, 
Organophosphates, Paracetamol etc) 
• Coexistent diseases like DM/CVS disease/ hepatic or 
renal disease/ malignant disease. 
• Those with severe infections. 
• Pregnant and lactating women. 
• Admitted after 24hrs of ingestion of poison. 
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3. One set of patients to receive 50gm activated 
charcoal dissolved in 400ml (2glasses) of water every 6hrs 
orally through nasogastric tube for three days. 
 
• Those who develop nausea/ vomiting  give Inj. 
metoclopramide 10mg IV. 
 
4. Second set of patients to receive 400ml (2 glasses) of 
sterile water every 6hrs for three days 
 
5. Other treatments/ Measures 
• Inj. atropine SOS (record the dose given) 
• Isoprenaline (record the dose given) 
• Do serum sodium, potassium, calcium, blood urea 
and serum creatinine 
• Do serial ECGs. 
• Look for life threatening cardiac arrhythmias and 
treat accordingly 
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6. Discharge criteria 
 
• Sinus rhythm with rate greater than 60per minute for 
24hrs. 
 
 
 
 
 
 
 
 
 25 
STATISTICAL ANALYSIS 
 
Statistical analysis was carried out for 47 subjects- 23 persons in 
the single dose activated charcoal and placebo group and 24 persons in 
the multiple dose charcoal group-after categorizing each variable.  
 
Patient’s age, sex, weight, no of seeds, seeds crushed or not, 
time taken after ingestion was matched. Other base line parameters 
like pulse rate, blood pressure, serum potassium level, serum sodium 
level, B. Urea, & S. Creatinine were analysed.  
 
Occurrence of cardiac arrhythmias at presentation and at 24 
hours after presentation, dose of atropine required, no of days for 
normalisation of ECG and duration of stay in hospital were 
evaluated& compared. Microsoft excel  and SPSS (Statistical package 
for social sciences) were used for analysis and Z tests were done to 
assess differences between percentages and difference between means. 
Analysis was by intention to treat. Statistical significance was taken 
when P<0.05. 
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OBSERVATIONS 
Table No 1 
Matching of placebo & activated charcoal groups 
 
Placebo 
Activated 
charcoal 
P 
Value 
Number 23 24  
Age (years) 25.74+7.75 26.75+10.11 0.69 
Male Sex (%) 11 (47.82%) 11(45.83) 0.92 
Height (cm) 156.48+11.83 158.83+9.32 0.42 
Weight (kg) 54.65+8.76 56.21+8.65 0.55 
Time after ingestion 
(hrs) 
4.64+3.63 5.28+4.57 0.62 
No of seeds 4.17+2.23 4.00+2.41 0.76 
Seeds-crushed or Not 
Yes(%) 
13 (56.52%) 19(79.16%) 0.09 
 
Data are mean [SD] unless stated otherwise. P value less than 
0.05 is considered statistically significant. Percentages are rounded off 
up to two decimals. SD means standard deviation.  
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Table No 2 
 
Base line characteristics & biochemical parameters 
 
 
Placebo Activated 
charcoal 
P 
Value 
Pulse rate 
(Per minute) 80.35+18.01 72.96+20.13 0.19 
Respiratory rate 
(breaths/ minute) 17.74+1.84 18.00+2.83 0.68 
Systolic BP 
(mm Hg) 110.61+11.03 114.43+14.19 0.32 
Diastolic BP 
(mm Hg) 71.39+9.99 74.43+12.21 0.37 
Serum Potassium 
(meq/L) 3.80+0.32 3.92+0.53 0.37 
Serum Sodium (meq/L) 133.39+5.72 134.54+4.02 0.42 
Serum creatinine 
(mg/dl) 0.95+ 0.18 1.02+0.21 0.23 
Blood Urea 
(mg/dl) 
 
27.35+6.01 27.21+4.06 0.92 
 
 
Data are mean (SD) unless stated otherwise. P value less than 
0.05 is considered statistically significant. Percentages are rounded off 
up to two decimals. SD means standard deviation. 
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Table No – 3 
Observations  
 
 
Placebo Activated 
charcoal 
P-
value. 
Mortality (%) 2(8.70%) 0(0%) 0.13 
Life threatening cardiac 
arrhythmias at 0 hrs(%) 1(4.34%) 7(29.16%) 0.02 
Major cardiac arrhythmias at   
0 hours (%) 8(34.78%) 11 (45.83%) 0.42 
Life threatening cardiac 
arrhythmias at 24 hours(%) 3(13.04%) 0(0%) 0.06 
Major cardiac arrhythmias at 
24 hrs(%) 7 (30.43%) 8(33.33%) 0.84 
Number of days for 
normalisation of ECG 3.05+1.02 2.92+0.97 0.62 
Dose of atropine required (in 
ampoules) 2.04+1.26 1.25+01.11 0.02 
Days of stay in hospital 3.17+1.06 3.29+0.75 0.69 
 
1 ampoule atropine =1.2mg atropine 
Data are mean (SD) unless stated otherwise. P value less than 
0.05 is considered statistically significant. Percentages are rounded off 
up to two decimals. SD means standard deviation 
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Table No 4 
Stratified analysis of atropine requirement 
 
 
Placebo Activated 
charcoal 
P 
value 
Dose of atropine required for patients 
presenting with life threatening cardiac 
arrhythmic at  0 hours (in no. of 
ampoules) 
3+ 0 2+ 1.29 0.036 
Dose of atropine required for patients 
presenting without life threatening 
cardiac arrhythmias at    0 hours (in no. 
of ampoules) 
2+ 1.27 0.94+ 0.90 0.003 
 
 
 Data are mean (SD) unless stated otherwise. P value less than 
0.05 is considered statistically significant. SD means standard 
deviation. 1 ampoule of atropine contains 1.2mg of atropine. 
 
 
Between June 1, 2004 and may 31, 2005, 63 patients were 
admitted to IMCU and poison centre of Madras Medical College, 
Chennai with yellow oleander seed poisoning. Of these, 47 fulfilled 
entry criteria and were randomly allocated to a treatment group.  
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All patients in the study group completed the trial; all had 
normal heart rates at the time they left hospital. Discharge criterion 
was sinus rhythm with rate greater than 60 per minute for 24 hours. 
 
Data from 47 patients participated in this study is finally 
entertained for analysis of which 23 patients belonged to placebo 
control group and 24 patients belonged to multiple dose activated 
charcoal group.  
 
The cases and controls are matched for age, sex, weight, time 
after ingestion of seeds, number of oleander seeds consumed, and for 
whether they are crushed seeds or not, as shown in table number 1. 
 
The cases and controls are age matched with a mean age of 
26.75 (Standard deviation 10.11) and 25.74 (standard deviation 7.75) 
respectively. P value is 0.69 and hence not significant (P value>0.05). 
 
Among the placebo plus single dose activated charcoal group 
47.82% were males whereas in the multiple dose activated charcoal 
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group males were 45.83%. P value 0.92 (P value >0.05). 
Furthermore the slight difference in sex balance between the two 
groups is unlikely to have had an effect on cardiac complications of 
poisoning in such a young population.  
 
Mean height of the patients in the cases was 158.83cm (Standard 
deviation 9.32) and in the control group 156.48 (Standard deviation 
11.83). P value 0.42 (P value >0.05) 
 
Weight of patients in the two arms of the trial were also 
matched, 54.65kg (standard deviation 8.76) and 56.21(standard 
deviation 8.65) in the control and cases respectively. P value 0.55 (P 
value >0.05). 
 
Another important parameter that was taken into consideration 
for matching was the time elapsed after consumption of oleander seeds 
until presentation to hospital. In the control group mean time after 
ingestion of seeds was 4.64 hours (standard deviation 3.63) and in the 
cases group it was 5.28 hours (standard deviation 4.57) with a P value 
of 0.62. (P value> 0.05). 
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Time after ingestion of seeds varied from 45 minutes to as late 
as 16 hours in the control group and 45 minutes to 22 hours in the 
multiple dose groups. In the placebo group 73.9% of patients 
presented within 6 hours after consumption of seeds (see table No5) 
where as in the treatment group 75% presented within 6 hours. 
 
Mean number of oleander seeds consumed in the control group 
was 4.17 with a standard deviation of 2.23, and in the cases, 4.00 with 
a standard deviation of 2.41. P value of 0.76 (P value >0.05). 
Although the median numbers of seeds ingested in the placebo and 
treatment group was 4.17 and 4.00 respectively, there was much 
variation in the number of seeds ingested. Two patients died in the 
placebo group took 3 seeds and 6 seeds respectively. Number of seeds 
taken varied from 1 seed to 8 seeds in the placebo group and 1 seed to 
11 seeds in the treatment group (see table no 6) 
 
Percentage of crushed seeds in the placebo group was 56.52% 
whereas in the treatment group 79.16%. p value 0.09. ( p value >0.05) 
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Base line characteristics and biochemical parameters of 
the patients are shown in table number 2. Mean pulse rate 80.35 per 
minute (standard deviation 18.01) and 72.96 per minute (standard 
deviation 20.13); respiratory rate 17.74 per minute (Standard 
deviation 1.84) and 18.00 per minute (standard deviation 2.83); 
systolic blood pressure 110.61 mm of Hg (standard  deviation 11.o3) 
and 114.43 mm of Hg (standard deviation 14.19); diastolic blood 
pressure71.39 mm of Hg (standard deviation 9.99) and 74.43 mm of 
Hg (standard deviation 12.21) were observed in the control and 
treatment group respectively. The P values were 0.10, 0.68, 0.32 and 
0.37 respectively. (All P values > 0.05). 
 
Mean serum potassium value in the control group was 3.8 meq/L 
(standard deviation 0.32) and in the charcoal group 3.92 meq/L 
(standard deviation 0.37). P value 0.37 ( P value > 0.05) 87.2% of 
patients had normal serum potassium values, and 10.6% had 
hypokalemia. Contrary to general perception, only 1 patient (2.1%) 
had hyperkalemia. (see table no 7) 
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Other biochemical parameters like serum sodium, serum 
creatinine and blood urea were unremarkable except the fact that 
majority of the patients in both arms were mildly hyponatremic; a 
mean of 133.39 meq/L (control group) and 134.54 meq/L (treatment 
group) (see table No7) 
 
Of the 63 patients admitted with oleander poisoning from June 
1, 2004 to May 31,2005, 4 persons died of cardiac arrhythmias ( a 
mortality rate of 6.35%). Of the 4 deaths, two deaths occurred within 
3 hours of admission, and hence excluded from the study.  
 
One of these two patients presented with complete heart block 
and later went for cardiac arrest. The other patient presented with 
ventricular tachycardia. Both these patients presented beyond 12 hours 
after consumption of oleander seeds and they took 5 seeds(crushed) 
and  3 seeds (not crushed) respectively. Pacing was attempted in the 
latter patient. 
 
Among the study groups, there were two deaths (8.70%) in the 
placebo controlled group whereas there was no death (0%)  in the 
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multiple dose group. But this reduction in mortality in the 
multiple dose arm was not statistically significant. P value 0.13. (P 
value >0.05). (See table No-3) 
 
The first of these two patients died in the placebo controlled 
group consumed 3 crushed seeds and presented within 8 hours. Initial 
ECG showed sinus rhythm with non- specific ST-T changes only. 13 
hours after admission she went for sudden cardiac arrest without any 
other major warning arrhythmias. 
 
Second patient had taken 6 crushed seeds and presented within 7 
hours of consumption and 13 hours later she went for cardiac arrest, 
preceded by ventricular tachycardia and multifocal atrial tachycardia. 
Pacing was tried in this patient also, but failed. 
 
210 patients admitted with oleander poisoning in the poison 
centre and IMCU of Madras Medical College, Chennai, during the 
period between September 1, 2001 to May 31, 2004; with a mortality 
rate of 11.43%. Compared to that the mortality rate in the study group 
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was 4.25% ( 2 out of 47). This reduction in mortality was 
statistically just significant. P value 0.05. 
 
 Incidence of major cardiac arrhythmias at presentation was 
comparable in the both arms of the trial, 34.78% in the placebo group 
and 45.83% in the multiple dose group. P value 0.42 (P value>0.05) 
(see table No-3). 
 
 However the incidence of life threatening arrhythmias at 
presentation was more in the activated charcoal group (29.16%) 
compared to placebo group (4.34%). P value 0.02. (P value <0.05). 
This is statistically significant and may be a bias involved in 
allocation.  
 
At presentation 29.8% had normal cardiac rhythm and 10.6% 
had sinus bradycardia. Non- specific ST-T changes were observed in 
19.2% of patients. Most common major cardiac arrhythmia was first 
degree AV block (14.9%), followed by second degree AV block type I 
(6.4%); Second degree AV block type II was seen  in 2.1% of patients.  
 
 37 
Other arrhythmias observed were sinus arrest (2.1%), 
complete heart block (2.1%) and atrial flutter (2.1%). One patient 
(2.1%) had first degree AV block and junctional rhythm occurring 
intermittently in a single ECG strip. Another patient (2.1%) had 
complete heart block and junctional rhythm in a single strip. 
Intermittent atrial fibrillation and second degree AV block type II 
were observed in another patient (2.1%). 
 
Of the 47 patients admitted 40.4% had major cardiac 
arrhythmias at presentation. One interesting observation is that all 
patients, presented after 12 hours of ingestion of oleander seeds had 
major cardiac arrhythmias (2 patients). Moreover two dead patients, 
excluded from the study, also presented more than 12 hours after 
consumption of seeds to hospital.  
 
15 out of the 19 patients (78.95%) who had major cardiac 
arrhythmia at presentation consumed crushed oleander seeds whereas 
only 4 (21.05%) took it without crushing. It appears that cardiac 
arrhythmias are more if seeds are crushed, though this has to be 
verified with detailed statistical analysis. 
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Occurrence of major cardiac arrhythmias 24 hours after initial 
presentation was comparable in each arm, 30.43% in placebo arm and 
33.33% in multiple dose arm. P value 0.84 (P value>0.05). There was 
a reduction in the occurrence of life threatening arrhythmias at 24 
hours in the multiple dose arm, 0% Vs 13.04% in the placebo arm. But 
this reduction is not statistically significant. P value 0.06 (P value 
>0.05). 
 
At 24 hours, 26.7% of patients had normal cardiac rhythm. Non- 
specific ST-T changes were observed in another 26.7%. 15.6% had 
sinus bradycardia. First degree AV block was the most common major 
cardiac arrhythmia at 24 hours, occurring in 24.4% of patients. 
Junctional rhythm was observed in 4.4% and second degree 2:1 AV 
block observed in 2.2% of patients. There was no case of atrial flutter 
/ fibrillation or ventricular tachycardia at 24 hours. 
 
Number of days taken for normalisation of ECG was almost 
equal in both groups, 3.05 days (standard deviation 1.02) in the 
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placebo group and 2.92 days (standard deviation 0.97) in the 
multiple dose group. P value 0.62 (P value > 0.05) 
 
There was no significant reduction in the number of days of 
hospitalisation required either; 3.17days (standard deviation 1.06) and 
3.29days (standard deviation 0.75) respectively. P value 0.69(P 
value>0.05). 
 
But this study found statistically significant reduction in the 
dose of drug- atropine- needed in the multiple dose treatment group. 
Placebo group patients required a mean dose of 2.04 ampoules of 
atropine (standard deviation 1.26) where as multiple dose group 
needed a mean dose of 1.25 (standard deviation 1.11) ampoules 
only.(1 ampoule of atropine contains 1.2mg of atropine). This 
reduction has a P value of 0.02 and hence statistically significant. (P 
value<0.05)  
 
Since there were significantly more number of life threatening 
arrhythmias in the multiple dose treatment group a stratified analysis 
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of the atropine requirement was carried out in patients 
presenting with life threatening cardiac arrhythmias and in those 
without.  
There was statistically significant reduction in the dose of 
atropine required in the multiple dose arm, even though life 
threatening arrhythmias were much more in this arm; 2 ampoules 
(standard deviation 1.29) verses  3 ampoules in the single dose group. 
P value 0.036 (P value < 0.05). 
 
This reduction in drug dose was more significant in patients 
presenting without life threatening cardiac arrhythmias; 2 ampoules 
(standard deviation 1.27) in the placebo controlled group and 0.94 
ampoules (standard deviation 0.90) in the treatment group. P value 
0.003 (P value <0.05). 
 
7 patients who had severe nausea after starting the trial were 
given 10mg of intravenous metoclopramide. The most frequent 
adverse effects of treatment with multiple doses of activated charcoal 
were abdominal discomfort, vomiting and diarrhoea. 2 patients had 
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diarrhoea and 18 patients developed vomiting. The side 
effects were transient and resolved without any specific treatment.  
 
Although most patients found the charcoal unpalatable, none 
refused to take it. Nine patients were given activated charcoal via a 
nasogastric tube. None developed aspiration or intestinal obstruction. 
No other complications were noted during the trial with the use of 
multiple dose activated charcoal. 
 
 
Table No. 5 
Time after ingestion of seeds at presentation 
 
 0-6 hrs        7-12 hrs 13-18 hrs 19-24 hrs 
Single 
dose (23) 
17 
(73.9%) 
5 
(21.7%) 
1 
(4.3%) 0 
Multiple 
dose (24) 
18 
(75%) 
5 
(20.8%) 0 
1 
(4.2%) 
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Table No. 6 
 
Number of seeds consumed 
 
 
 
Table No. 7 
 
Serum Potassium level 
 
 
 
< 3.5 
meq/L 
3.5 – 5.0 
meq/L 
> 5.0 
meq/L 
Single 
dose (23) 
3 
(13.0%) 
20 
(87.0%) 
0 
 
Multiple 
dose (24) 
2 
(8.3%) 
21 
(87.5%) 
1 
(4.2%) 
 
 1-2 seeds 3-4 seeds 5-6 seeds 7-8 seeds > 8 seeds 
Single 
Dose (23) 
5 
(21.7%) 
11 
(47.8%) 
2 
(8.7%) 
5 
(21.7%) 0 
Multiple 
dose (24) 
6 
(25.0%) 
10 
(41.7%) 
5 
(20.8%) 
2 
(8.3%) 
1 
(4.2%) 
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Cardiac arrhythmias at presentation 
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`Cardiac arrhythmias at 24 hours 
 
 
26.7 26.7
15.6
0
24.4
0 0
2.2
0 0
4.4
0 0
0.0
5.0
10.0
15.0
20.0
25.0
30.0
N
o
rm
a
l
N
o
n
 
sp
e
ci
fic
 
ST
-
T 
ch
a
n
ge
s
Si
n
u
s 
br
a
dy
ca
rd
ia
Si
n
u
s 
a
rr
e
st
1s
t d
e
gr
e
e
 
AV
 
bl
o
ck
2 
n
d 
de
gr
e
e
 
AV
 
bl
o
ck
 
ty
pe
 
I
2n
d 
de
gr
e
e
 
AV
 
bl
o
ck
 
ty
pe
 
II
2:
1 
Bl
o
ck
CH
B
At
ria
l f
ib
ril
la
tio
n
Ju
n
ct
io
n
a
l r
hy
th
m
VT
At
ria
l f
lu
tte
r
Pe
rc
en
ta
ge
 
of
 
ar
rh
yt
hm
ia
s
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
43 
DISCUSSION 
 
In this study of Indian population involving 47 patients, the aim 
was to assess the efficacy of multiple dose activated charcoal in the 
treatment of patients with yellow oleander poisoning. 
 
Regarding base line parameters, the study showed no significant 
correlation with biochemical parameters like serum potassium, serum 
sodium or serum creatinine in the outcome of the patients in both arms 
of the trial. Most of the patients (87.2%) had normal potassium levels 
in serum and only 1 patient (2.1%) had hyperkalemia. This finding is 
in contrast to the study by Eddleston M, Ariaratnam et al16. where they 
reported hyperkalemia is very common in oleander seed poisoning. 
 
According to the study by D.A. Warrel, Eddleston M et al most 
common cardiac arrhythmias in acute oleander poisoning were AV 
nodal and sinus nodal dysfunction, and ventricular arrhythmias were 
rare. In digoxin poisoning, the arrhythmia profile is different and 
ventricular ectopics and tachycardia are fairly common.  
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These observations are supported in this present study too. Most 
of the arrhythmias observed were of sinus node or AV node 
dysfunction and ventricular arrhythmias were extremely rare, both at 
initial presentation and after 24 hours. Only 2.1 percentage of patients 
had ventricular arrhythmias at presentation and none at 24 hours. Most 
common major cardiac arrhythmia both at presentation and 24 hours 
after initial presentation was first degree AV block. 
 
According to similar trial done by H.A. De Silva et al21 in Sri 
Lanka, 2002, there was 69% reduction in death rate when multiple 
dose charcoal was used, compared with a placebo. They also found 
significant reduction in the occurrence of major arrhythmias at 24 
hours and in the doses of atropine in the multiple dose treatment arm. 
 
However in the present study, though there was a reduction in 
mortality in the multiple dose arm; zero verses two; this was not 
statistically significant. This could be due to smaller sample size in 
this study. Moreover most of the patients presented with life 
threatening arrhythmias were allocated to the multiple dose treatment 
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arm. This would have further decreased mortality, in the placebo 
controlled arm. 
 
Another interesting finding was that the poison centre and 
IMCU of Madras Medical College had a mortality rate of 11.43 
percentage among 210 patients admitted between September 1, 2001 
to May 31, 2004. In the current study which included 47 patients 
admitted from June 1, 2004 to May 31, 2005 the mortality rate was 
only 4.25%. This is statistically just significant.  
 
This reduction in mortality could be attributed to the use of 
multiple dose activated charcoal in over half of these patients. Again 
its noteworthy here that most of the patients with life threatening 
arrhythmias at presentation received multiple dose activated charcoal. 
 
Occurrence of major cardiac arrhythmias 24 hours after initial 
presentation was comparable in both arms of the trial. But there was 
reduction in the occurrence of life threatening cardiac arrhythmias at 
24 hours in the multiple dose activated charcoal treatment arm; zero 
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percentage verses 13.04 percentage in the placebo arm. But this 
reduction is not statistically significant.    
 
In the study by H.A. de Silva et al21, there was significant 
reduction in occurrence of life threatening cardiac arrhythmias at 24 
hours in the multiple dose group. The smaller sample size in the 
current study may be the cause for the statistical insignificance. 
 
Number of days taken for normalisation of ECG was comparable 
in both arms of the trial. Also there was no significant reduction in the 
number of days of hospitalisation required. The Sri Lankan study by 
H.A. de Silva also showed similar results. 
 
The current study found statistically significant reduction in the 
dose of drug atropine needed in the multiple dose treatment group. 
Since there was significantly more number of life threatening 
arrhythmias in the multiple dose treatment group, a stratified analysis 
of the atropine requirement was carried out in patients presenting with 
life threatening cardiac arrhythmias and in those without. 
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There was statistically significant reduction in the dose of 
atropine required in the multiple dose arm, even though life-
threatening arrhythmias were more in this arm. This reduction in drug 
dose was more significant in patients presenting without life 
threatening arrhythmias. 
 
The need for early treatment to prevent death after poisoning 
with yellow oleander is emphasised by the fact that all the deaths 
during the study period occurred within 13 hours of admission. Also 
all the patients presented more than 12 hours after consumption of 
oleander seeds had major cardiac arrhythmias.  
 
Furthermore, some of the patients had sudden cardiac events 
causing death; that were not preceded by arrhythmias suggestive of 
the need for temporary cardiac pacing or antidigoxin antibody fab 
fragments. All patients in our study were treated within 24 hours of 
poisoning. 
 
In this study activated charcoal was found to have been tolerated 
well and had no serious side effects. It is noteworthy that in yellow 
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oleander poisoning, activated charcoal acts not only through 
prevention of the initial absorption of the toxic glycosides, but also by 
preventing toxin reabsorbtion after intestinal secretion from the 
systemic circulation.  
 
The effectiveness of activated charcoal in reducing the severity 
of yellow oleander poisoning is lent support by the fact that the dose 
of atropine required in the multiple dose arm was much lower, even 
though this arm included majority of the patients with life threatening 
cardiac arrhythmias at presentation.  
 
However, current study could not show statistically significant 
reduction in mortality and occurrence of life threatening cardiac 
events at 24 hours after admission, in the activated charcoal treated 
group. A larger sample size is required to confirm this conclusion. 
 
In our country, patients from rural areas who need temporary 
cardiac pacing for life threatening bradyarrhythmias after yellow 
oleander poisoning are usually transferred to a tertiary care centre. 
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Such transfers and cardiac pacing are costly and have resulted in 
deaths during transit.  
 
Treatment with anti-digoxin antibody fab fragments is very 
expensive and not widely available. And some of the patients may 
require more than one dose. Thus there is a pressing need for an 
inexpensive and effective treatment that can be used in non-urban 
hospitals. Activated charcoal is easily available and            
inexpensive. 
 
Multiple dose activated charcoal is safe and effective and should 
be given to all patients who have ingested yellow oleander seeds. 
Expensive interventions such as cardiac pacing and anti-digoxin 
antibody fab fragments could be reserved for patients who have 
dangerous arrhythmias at the time of presentation with oleander 
poisoning or those who develop arrhythmias despite treatment with 
activated charcoal. 
 
It is probable that the multiple dose activated charcoal could 
also be of use in the treatment of patients who have been poisoned 
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with other cardiac glycosides. A previous study in 23 patients25 and a 
few anecdotal reports26 have shown that charcoal increases the 
clearance rate of digoxin, and experimental evidence shows much the 
same effect on digitoxin clearance.26 
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CONCLUSION 
 
The following are conclusions from the study  
 
1. Multiple dose activated charcoal is safe and effective in 
the treatment of oleander seed poisoning and it reduced 
the atropine requirement significantly. 
 
2. It is effective in reducing death and life threatening 
cardiac arrhythmias in oleander seed poisoning. But this 
reduction is not statistically significant. This impression in 
this study may be due to smaller sample size. 
 
 
3. There was no reduction in the number of days of stay in 
the hospital or in the number of days taken for 
normalisation of ECG.  
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SCOPE FOR FUTURE STUDIES 
 
1. As already stated, the reduction in mortality and life threatening 
cardiac arrhythmias by multiple dose activated charcoal in the 
treatment of oleander seed poisoning has to be verified with a 
larger sample size. 
 
2. Multiple dose activated charcoal could also be of use in patients 
who have been poisoned with other cardiac glycosides like 
digoxin, odollam (cerbera odollam) etc. Odollum poisoning is 
very common in south India, whose active principle is cerberin 
(thevetin-B), which is same as that contained in yellow 
oleander. So activated charcoal may have a potent role in the 
treatment of odollum poisoning. 
 
3.  As the oleander seeds produce a toxic carditis like picture many 
cardiologists advise anti inflammatory agents like 
corticosteroids. At the poison centre of our hospital, as advised 
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by cardiologist, 10 patients received corticosteroids during the 
study period. These patients were excluded from this study. To 
evaluate the role of steroids in oleander seed poisoning, further 
studies are required.
 PROFORMA 
Name:  Age:   Sex:   IP No: 
Height:  Weight:  Unit:   DOA: 
 
1. Time after ingestion : 
2. Number of seeds : 
3. Pulse rate  : 
4. Respiratory rate : 
5. Blood pressure : 
6. Serum Potassium : 
  Sodium : 
  Creatinine : 
  Calcium : 
  Blood urea :  
7. Dose of atropine 
     given (total) : 
8. Dose of isoprenaline 
         given (total) : 
9. ECG 
      Day 1  : 
 Day 2  : 
 Day 3  :
  
 
S. No Name Age Sex Ht Wt Time Seed 
no. 
Crushe
d PR RR SBP 
DB
P K Na Cr Urea 
Life 
ECG 
0 hrs 
Major 
ECG 0 
hrs 
Life ECG 
24 hrs 
Major 
ECG 
24 hrs 
Norma
l ECG 
days 
Drug 
S
t
a
y 
1 Yuvaraj 20 M 165 65 1 8 N 86 18 110 70 3.2 133 0.8 20 N N N N 4 4 4 
2 Ramesh 27 M 117 68 4 3 Y 100 16 100 70 3.8 136 1.3 26 N Y N Y 4 4 5 
3 Vartha 24 F 150 46 1 5 N 90 20 110 80 3.9 136 1.1 32 N N N N 1 0 3 
4 Murugan 23 M 164 54 4 4 Y 100 16 100 80 3.6 140 0.7 18 N N N N 3 1 4 
5 Ramachandran 45 M 168 65 1 2 N 80 16 130 80 4.6 128 0.9 34 N N N N 1 0 3 
6 Sheela 26 F 148 52 8 4 Y 68 22 130 70 3.7 131 0.9 20 N Y N Y 4 3 4 
7 Gowrinathan 39 M 162 55 6 6 Y 90 16 120 80 3.8 133 0.9 36 N N Y Y 4 3 4 
8 Sadasivam 30 M 172 70 7 3 Y 92 16 100 60 3.5 138 0.9 35 N N N N 3 2 3 
9 Komathy 30 F 156 50 16 3 N 56 16 110 70 3.4 135 0.9 26 N Y N N 3 2 3 
10 Muthalagu 34 M 170 72 0.75 3 Y 108 20 120 80 4.4 116 1.0 30 N N N N 3 2 3 
11 
 
Prakash 21 M 168 54 4 3 Y 62 16 100 70 3.8 136 0.9 30 N N N N 3 2 3 
12 
 
Janaki 22 F 162 53 9.5 4 Y 60 16 110 70 3.9 132 0.6 36 N Y N Y 3 3 3 
13 Shanmugam 20 M 166 57 4 8 Y 86 16 130 80 3.2 130 0.8 20 N N N N 4 3 3 
14 Vruthambal 15 F 148 44 8 3 Y 64 18 110 80 4.1 136 0.7 18 N N expired - - 1 .5 
15 Selvi 36 F 154 58 6 7 Y 70 20 110 70 3.7 130 0.9 26 N Y expired - - 4 .5 
16 Poongavanam 28 F 152 54 1.5 2 N 84 18 116 74 3.6 128 0.9 22 N N N N 1 0 3 
17 Valliammal 29 F 155 50 2.5 2 Y 96 18 110 60 3.7 130 1.1 26 N N N N 3 1 3 
18 Kamala 30 F 148 48 5 2 Y 60 18 100 70 4.0 134 1.3 30 N Y N Y 4 2 4 
19 Seshadri 24 M 165 60 1 8 N 50 20 110 70 3.9 140 1.1 22 N N N N 2 1 2 
20 Manimegalai 16 F 154 42 3.5 3 N 56 20 96 60 3.7 130 1.0 26 N Y N Y 4 3 4 
21 Renuka 17 F 150 48 7 4 N 88 18 100 70 3.9 134 1.1 32 N N N N 4 2 4 
22 Balaji 16 M 160 52 1 1 N 90 16 126 88 3.9 136 1.1 36 N N N N 3 1 3 
23 Yasodha 20 F 145 40 5 8 N 112 18 96 40 4.0 146 1.0 28 Y Y N Y 3 3 4 
Single dose charcoal 
 S.No 
 
 
Name Age Sex Ht Wt Time Seed 
no. 
Crushed PR RR SBP DBP K Na Cr Urea 
Life 
EC
G 0 
hrs 
Major 
ECG 
0 hrs 
Life 
ECG 
24 
hrs 
Majo
r 
ECG 
24 
hrs 
Norma
l 
ECG 
days 
Dru
g 
Days 
stayed 
1 Sarangapani 45 M 168 64 3 3 Y 52 16 140 100 4.1 136 1.1 24 N N N N 2 3 2 
2 Karthik 14 M 156 46 6 1 Y 48 16 100 70 4.3 140 0.9 24 N N N Y 4 2 4 
3 Prakasham 55 M 171 65 1.5 3 Y 72 16 110 90 3.9 140 0.9 28 N N N N 4 1 4 
4 Rajendran 39 M 168 70 22 7 Y 76 18 120 70 4.1 139 1.2 32 N Y N Y 3 0 3 
5 Gangamma 27 F 152 53 1 2 Y 54 16 100 70 3.6 136 1.3 28 N Y N N 4 1 4 
6 Anandhi 35 F 154 60 5 3 Y 84 18 120 80 2.4 138 0.8 25 N N N N 1 0 3 
7 Geetha 29 F 150 58 11 2 Y 80 18 140 80 3.2 138 0.8 24 N N N N 3 1 3 
8 Saravanakum
ar 
20 M 171 66 4 1 N 80 20 100 70 3.8 134 1.0 26 N N N N 2 0 2 
9 Girija 15 F 144 44 1 5 N 110 16 120 70 3.6 128 0.7 23 N N N N 2 1 3 
10 Jayanthi 22 F 154 51 0.75 2 Y 90 18 110 70 4.1 130 1.1 30 N N N N 1 0 2 
11 Kannan 26 M 174 71 6 3 Y 90 16 116 80 4.3 138 1.3 34 N Y N Y 3 1 3 
12 Kandan 38 M 168 62 2 4 N 52 18 130 86 3.9 132 1.2 30 N N N N 3 2 4 
13 Kannan 17 M 164 50 3 4 Y 80 16 110 70 3.7 132 1.1 32 N N N N 3 0 3 
14 Selvi 28 F 156 54 6 1 Y 90 18 110 80 4.3 133 1.1 22 N N N N 3 1 3 
15 Sumathi 20 F 154 48 3 8 N 66 16 114 70 4 136 1.0 29 N Y N Y 3 2 3 
16 Srinivasan 25 M 170 66 8 3 Y 100 20 140 90 4.6 138 1.1 34 N N N N 3 1 3 
17 Seetha 17 F 150 48 2 3 Y 96 18 116 70 3.8 140 0.9 24 N N N N 3 0 3 
18 Amutha valli 29 F 150 48 4 6 Y ? 12 ? ? 3.7 134 1.6 28 Y Y N Y 3 1 4 
19 Kumar 25 M 172 70 9 11 N 80 20 96 60 4.1 130 0.9 32 Y Y N N 2 1 4 
20 Porkodi 18 F 146 46 3 4 Y 44 16 110 70 4.2 130 0.8 30 Y Y N N 5 4 5 
21 Kalaiselvi 23 F 152 54 10 6 Y 54 22 100 60 5.3 138 0.8 26 Y Y N Y 3 3 3 
22 Mahesh 19 M 162 48 4.5 3 Y 58 20 110 50 3.8 131 0.8 24 Y Y N Y 4 3 4 
23 Prema 21 F 156 51 4 5 Y 88 26 130 96 3.9 130 1.1 18 Y Y N N 4 1 4 
24 Vasantha 35 F 150 56 7 6 Y 34 22 90 60 3.3 128 1.0 26 Y Y N Y 2 1 3 
 
 
Multiple dose charcoal 
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